Peanut allergy uptodate reflects a rapidly evolving landscape in food allergy management, with new clinical insights and refined guidelines shaping care. This article synthesizes the latest evidence on prevention, diagnosis, treatment options, and long-term strategies for patients and clinicians.
Staying current with peanut allergy uptodate information helps reduce uncertainty, improve safety, and support shared decision-making for individuals at risk and their families. The following sections organize key topics to support practical understanding and application.
| Topic | Key Guideline Source | Preventive Approach | Typical Diagnostic Threshold |
|---|---|---|---|
| Introduction and Risk Overview | AAAAI, EAACI 2023-2024 | Early introduction around 4-6 months in infants without severe eczema | ≥5 kU/L or positive skin test to peanut |
| Primary Prevention Strategies | LEAP trial follow-up, NIAID guidance | Regular peanut consumption in high-risk infants under supervision | Oral food challenge if history of mild reaction or equivocal testing |
| Diagnosis and Testing Approach | WAO, Joint Task Force 2023 | Age-appropriate introduction alongside other solids | Component-resolved diagnostics to differentiate sensitization from clinical allergy |
| Management and Emergency Plans | AAAAI position paper, EAACI guidelines | Strict avoidance of peanut and cross-contact education | Prescription of epinephrine autoinjectors and clear anaphylaxis action plan |
| Emerging Therapies and Monitoring | Palforzia real-world data, oral immunotherapy trials | Ongoing monitoring of tolerance and dose adjustments | Periodic oral food challenges or baked peanut challenges as indicated |
Primary Prevention in Early Infancy
Guidance for High and Low Risk Infants
Current peanut allergy uptodate guidance emphasizes early, age-appropriate introduction of peanut-containing foods, starting around 4 to 6 months, to lower the risk of developing peanut allergy. For infants with severe eczema or existing egg allergy, introducing peanut under clinical supervision is strongly recommended rather than delayed. In infants without these risk features, offering peanut at home in an age-safe form is encouraged to harness protective effects observed in landmark studies such as the LEAP trial.
Diagnostic Evaluation and Testing
Interpreting Skin Tests and Specific IgE
Up-to-date diagnostic approaches combine a detailed history with targeted testing to distinguish sensitization from clinically relevant peanut allergy. Skin prick tests and specific IgE measurements to whole peanut and component markers help refine risk, while supervised oral food challenges remain the diagnostic gold standard when history or tests are inconclusive. Component-resolved diagnostics are increasingly used to predict the likelihood of reactions to heat-processed peanut and to guide management decisions.
Ongoing Management and Safety Planning
Avoidance, Education, and Emergency Readiness
Effective peanut allergy uptodate management centers on strict avoidance of peanut and hidden sources, supported by clear instructions for label reading and cross-contact reduction in home, school, and food service settings. Patients and caregivers should receive training on recognizing early symptoms, using epinephrine autoinjectors promptly, and activating emergency medical services for any systemic reaction. A written anaphylaxis action plan that details when and how to administer epinephrine, when to call emergency services, and follow-up steps is essential.
Emerging Therapies and Long-Term Monitoring
Oral Immunotherapy, Palforzia, and Real-World Use
Peanut allergy uptodate care now includes newer options such as oral immunotherapy and the approved product Palforzia, aimed at raising the threshold of reactivity and reducing the risk of accidental reactions. These approaches require careful patient selection, structured protocols, and ongoing monitoring for dose-related reactions and efficacy. Shared decision-making should weigh potential benefits against the risk of side effects, the commitment to regular dosing, and the need for continued epinephrine availability even after successful desensitification.
Key Takeaways and Recommendations
- Introduce age-appropriate peanut around 4-6 months, especially after discussing risk with your pediatrician.
- Use supervised oral food challenges and component testing to clarify diagnosis when history or results are uncertain.
- Maintain strict peanut avoidance and clear label-reading habits as part of daily management.
- Keep epinephrine autoinjectors accessible and ensure caregivers and close contacts know how to use them.
- Discuss emerging therapies such as oral immunotherapy or Palforzia with an allergist to understand benefits, risks, and long-term commitments.
FAQ
Reader questions
Can introducing peanut early really prevent peanut allergy in my baby?
Yes, current evidence supports introducing age-appropriate peanut-containing foods around 4 to 6 months in most infants, which can substantially reduce the risk of developing peanut allergy. High-risk infants with severe eczema or egg allergy should be introduced under clinical guidance, while others can typically try peanut at home if introduced alongside other solids.
How reliable are skin tests and blood tests for peanut allergy?
Skin tests and blood tests for peanut-specific IgE are useful but not definitive on their own; they indicate sensitization and can help estimate the chance of a reaction. A supervised oral food challenge is often necessary to confirm or rule out clinical allergy, especially when test results are borderline or the history is unclear.
Is baked peanut safe for someone with a peanut allergy?
Some individuals with peanut allergy can tolerate baked peanut because the heating process alters certain proteins, but this varies by person. An allergist can assess tolerance through history and, if appropriate, supervised baked peanut challenges before incorporating it regularly into the diet. Even if no reaction occurs initially, observe for delayed symptoms and ensure easy access to epinephrine and medical support, because biphasic reactions can occur. Contact your healthcare provider or seek care if any concerning signs develop, and review your anaphylaxis action plan for future steps.